Abstract

Summary

This in vitro study demonstrates that melatonin inhibits estrogen-dependent breast cancer growth by suppressing aromatase expression in malignant epithelial, peritumoral adipose, and vascular endothelial tissues, partly through reduced PGE2 and cyclooxygenase activity. These findings suggest melatonin may serve as a complementary oncostatic agent by targeting multiple estrogen biosynthesis pathways and anti-angiogenic mechanisms in the tumor microenvironment.
Abstract

Key Findings

  • Melatonin inhibited aromatase expression in malignant epithelial tissue via aromatase promoters pII and pI.3, mediated by decreased PGE2 levels through suppression of cyclooxygenase activity and expression.
  • Melatonin reduced aromatase activity and expression in peritumoral adipose tissue and promoted fibroblast differentiation by increasing PPARγ and C/EBPα transcription factors.
  • Melatonin suppressed anti-adipogenic cytokines (TNFα, IL-6, IL-11) secreted by malignant epithelial cells and fibroblasts, inhibiting the desmoplastic reaction.
  • Melatonin exerted anti-angiogenic effects by inhibiting vascular endothelial cell proliferation, invasion, migration, and tubular structure formation, and suppressed aromatase gene expression via promoter pI.7 in endothelial cells.
  • Melatonin modulated VEGF secretion by malignant epithelial cells by inhibiting both VEGF gene expression and protein production.
Categories

Categories

Sleep & Circadian Health: Melatonin, the primary pineal gland secretion central to circadian regulation, is studied here for its oncostatic mechanisms in breast cancer tissue models.
Patient Recovery: The study examines melatonin's anti-tumor, anti-angiogenic, and stromal-modulating effects in breast cancer models, with implications for oncology treatment support.
Authors

Author(s)

V Álvarez García
Publication Date

Publication Year

2013
View more publications